Payment overview · 2025
General Payments
$1,281.63
67 reported records · 23 companies
Healthcare provider profile · identity verified
Mark Alan Earhart, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · WATKINSVILLE, GA · NPI 1073536439
Verified facts
What the public records show
CMS Open Payments records show Mark Alan Earhart, M.D. received $1,281.63 in general payments during 2025 across 67 reported records.
Novo Nordisk Inc accounted for 29.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 37 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Shingrix, Trintellix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Eliquis by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $374.24 | 29.2% | 19 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $147.02 | 11.5% | 8 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $96.66 | 7.5% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $76.81 | 6.0% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $69.36 | 5.4% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $52.15 | 4.1% | 3 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $48.87 | 3.8% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $47.67 | 3.7% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$38.51 | 3.0% | 2 | 2025 |
| Noven Therapeutics, LLC | Unresolved — no canonical attribution shown | $37.64 | 2.9% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $31.40 | 2.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $30.77 | 2.4% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $30.02 | 2.3% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $28.23 | 2.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $24.24 | 1.9% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $21.03 | 1.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.86 | 1.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.86 | 1.5% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $18.65 | 1.5% | 1 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $18.34 | 1.4% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $17.30 | 1.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.91 | 1.3% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $16.09 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,281.63 | 67 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $309.22 | 14 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $147.02 | 8 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $96.66 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $74.81 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $65.02 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $53.89 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $52.15 | 3 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $48.87 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $44.01 | 2 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $38.51 | 2 | 2025 |
Source payment records
|
|||||
| Xelstrym Normalized: xelstrym |
Drug | Noven Therapeutics, LLC | $37.64 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $34.74 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $34.24 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $31.40 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $31.26 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $31.26 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $30.77 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $30.02 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $28.23 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $24.24 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $21.03 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $20.86 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $19.65 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.86 | 1 | 2025 |
Source payment records
|
|||||
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $18.34 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $17.30 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $17.30 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $17.17 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.91 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.91 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.41 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.41 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.63 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $15.47 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $15.47 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $15.47 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.12 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 46 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 103 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 27 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
27 | 21 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
103 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 240 | 69 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 163 | 23 |
| Atorvastatin Calcium | Atorvastatin Calcium | 159 | 52 |
| Zolpidem Tartrate | Zolpidem Tartrate | 152 | 25 |
| Amlodipine Besylate | Amlodipine Besylate | 151 | 45 |
| Clonazepam | Clonazepam | 139 | 30 |
| Levothyroxine Sodium | Levothyroxine Sodium | 137 | 42 |
| Gabapentin | Gabapentin | 129 | 39 |
| Prednisone | Prednisone | 129 | 66 |
| Montelukast Sodium | Montelukast Sodium | 109 | 31 |
| Omeprazole | Omeprazole | 109 | 39 |
| Celecoxib | Celecoxib | 103 | 32 |
| Ozempic | Semaglutide | 103 | 19 |
| Metformin Hcl | Metformin Hcl | 91 | 31 |
| Lisinopril | Lisinopril | 87 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 87 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 84 | 23 |
| Alprazolam | Alprazolam | 79 | 14 |
| Simvastatin | Simvastatin | 76 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 75 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 75 | 24 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 72 | 12 |
| Lorazepam | Lorazepam | 67 | 16 |
| Metoprolol Succinate | Metoprolol Succinate | 67 | 25 |
| Furosemide | Furosemide | 65 | 22 |
| Carvedilol | Carvedilol | 60 | 18 |
| Trazodone Hcl | Trazodone Hcl | 52 | 13 |
| Telmisartan | Telmisartan | 51 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 50 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 50 | suppressed |
| Potassium Chloride | Potassium Chloride | 48 | 18 |
| Temazepam | Temazepam | 48 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 47 | 15 |
| Pantoprazole Sodium | Pantoprazole Sodium | 47 | 16 |
| Mounjaro | Tirzepatide | 46 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 45 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 43 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 41 | 15 |
| Spironolactone | Spironolactone | 41 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 40 | 14 |
| Meloxicam | Meloxicam | 40 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 40 | 11 |
| Pregabalin | Pregabalin | 40 | suppressed |
| Ondansetron Odt | Ondansetron | 39 | 12 |
| Tramadol Hcl | Tramadol Hcl | 39 | 13 |
| Cefdinir | Cefdinir | 38 | 24 |
| Allopurinol | Allopurinol | 37 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 36 | suppressed |
| Methylprednisolone | Methylprednisolone | 34 | 29 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 34 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 32 | 13 |
| Sertraline Hcl | Sertraline Hcl | 32 | 11 |
| Fenofibrate | Fenofibrate | 31 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 30 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 22 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 29 | suppressed |
| Aripiprazole | Aripiprazole | 29 | suppressed |
| Jardiance | Empagliflozin | 29 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 29 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 24 |
| Baclofen | Baclofen | 27 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 27 | suppressed |
| Losartan Potassium | Losartan Potassium | 27 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 27 | 21 |
| Oxycodone Hcl | Oxycodone Hcl | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Eliquis | Apixaban | 25 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 25 | suppressed |
| Fluconazole | Fluconazole | 24 | 17 |
| Ezetimibe | Ezetimibe | 23 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Olanzapine | Olanzapine | 22 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 21 | 11 |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Famotidine | Famotidine | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 17 | suppressed |
| Azithromycin | Azithromycin | 16 | 13 |
| Lovastatin | Lovastatin | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 13 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Humalog | Insulin Lispro | 13 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Sulindac | Sulindac | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Novolog | Insulin Aspart | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,281.63 · 67 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, Azstarys, BREZTRI, CAPLYTA, COMIRNATY, Dexcom G6 Transmitter, Dyanavel XR, ELIQUIS, EVENITY, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, FREESTYLE LIBRE 3, JARDIANCE, Kerendia, Leqembi, MINIMED 780G, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, PROLIA, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, TRINTELLIX, UBRELVY, WAKIX, Wegovy, XIFAXAN, Xelstrym, ZAVZPRET, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error